MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2024013059

Медицинская библиотека · Blood advances · 2024

Optimizing liver health before and after gene therapy for hemophilia A.

Ragni Margaret V, Mead Henry, de Jong Ype P, Kaczmarek Radoslaw, Leavitt Andrew D, Long Brian, Nugent Diane J, Sabatino Denise E, Fong Sylvia, von Drygalski Annette, Walsh Christopher E, Luxon Bruce A

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Gene therapy for severe hemophilia A uses an adeno-associated virus (AAV) vector and liver-specific promoters that depend on healthy hepatocyte function to achieve safe and long-lasting increases in factor VIII (FVIII) activity. Thus, hepatocyte health is an essential aspect of safe and successful gene therapy. Many people living with hemophilia A have current or past chronic hepatitis C virus infection, metabolic dysfunction-associated steatosis or steatohepatitis, or other conditions that may compromise the efficacy and safety of AAV-mediated gene therapy. In addition, gene therapy may induce an immune response to transduced hepatocytes, leading to liver inflammation and reduced FVIII activity. The immune response can be treated with immunosuppression, but close monitoring of liver function tests and factor levels is necessary. The long-term risk of hepatocellular carcinoma associated with gene therapy is unknown. Routine screening by imaging for hepatocellular carcinoma, preferable every 6 months, is essential in patients at high risk and recommended in all recipients of hemophilia A gene therapy. This paper describes our current understanding of the biologic underpinnings of how liver health affects hemophilia A gene therapy, and provides practical clinical guidance for assessing, monitoring, and managing liver health both before and after gene therapy.

Для цитирования: Ragni Margaret V, Mead Henry, de Jong Ype P, Kaczmarek Radoslaw, Leavitt Andrew D, Long Brian, Nugent Diane J, Sabatino Denise E, Fong Sylvia, von Drygalski Annette, Walsh Christopher E, Luxon Bruce A. Optimizing liver health before and after gene therapy for hemophilia A.. Blood advances. 2024. DOI: 10.1182/bloodadvances.2024013059.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.